Publications by authors named "M Villedieu"

Claim this Profile
T
The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl-x or Mcl-1 in ovarian cancer.
Cécilia Thomine, Sterenn Guillemot, Louis-Bastien Weiswald, Romane Florent, Edwige Abeilard, Marie Villedieu

Mol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary angioedema in children: Review and practical perspective for clinical management.
Anne Pagnier, Angelina Dermesropian, Charlotte Kevorkian-Verguet, Mélisande Bourgoin-Heck, Cyrille Hoarau, Mona Villedieu

Pediatr Allergy Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
Lucie Thorel, Pierre-Marie Morice, Hippolyte Paysant, Romane Florent, Guillaume Babin, Marie Villedieu

J Exp Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy of immunoglobulins in small fiber neuropathy related to Sjögren's syndrome.
Taylor Pindi Sala, Mona Villedieu, Laura Damian, Jean-Charles Crave, Vivien Pautot

J Neurol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Cécile Pétigny-Lechartier, Charlène Duboc, Abdelghani Jebahi, Marie-Hélène Louis, Edwige Abeilard, Marie Villedieu

Mol Cancer Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis